Performance Evaluation of FullCeram Implants in Single Tooth Gaps

Not Applicable

Completed

Brief Summary: * Straumann Monotype FullCeram implants serve as a suitable alternative for implant therapy especially in the aesthetic zone

* The survival rate of Straumann Ceramic implants should be at least 85% (max 6 implant losses out of 40 patients) after the first year

Detailed Description: This is a prospective, open label, single arm, multicenter study. The total study duration for each patient was prolonged to 10 years follow-up. It is acceptable to have the visit performed up to 6 month after the aspired date.

The primary study parameter will be analyzed as soon as every patient passed visit 6 (annual follow-up visit, 12 month +/- 4 weeks).

Implants will be placed transmucosally and will be protected by a thermoplastic splint for healing. A provisional prosthesis will be placed (out of occlusion) 12-14 weeks post implant placement. The final crown will be done between study week 24 and 28. Implant survival, implant success, bone loss, periodontal parameters and adverse events will be assessed in the follow-up visits.

In total 10 visits are scheduled in this study. The investigational device: Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm. This is a CE marked product.

Three centres in Germany are participating. The study and any amendments will be performed as far as possible according to ISO 14155 (Second Edition, 2011-02-01) and conform to the Declaration of Helsinki (last revised Seoul 2008) and local legal and regulatory requirements.

Recruitment & Eligibility

Inclusion Criteria

Subject must have voluntary signed the informed consent and the data protection consent form before any study related action
Males and females with at least 18 years of age (including 18 years)
Implant placement planned in the maxilla or mandible
The missing tooth site must have a tooth with a natural root
Substantially healed and augmented extraction sockets (minimal 8 weeks)
Autogenous bone augmentation until 3 month pre-implantation were bone deficiency jeopardizing the implant position

Exclusion Criteria

Pre-surgical exclusion criteria:

Systemic disease that would interfere with dental implant therapy
Any contraindications for oral surgical procedures
Mucosal diseases
History of local irradiation therapy
Current untreated periodontitis or gingivitis
Any untreated endodontic lesions
Probing pocket depth of > or = 4 mm on one of the teeth immediately adjacent to the dental implant site
Severe bruxing or clenching habits
Patients with inadequate oral hygiene or unmotivated for adequate home care
Patients who smoke >10 cigarettes per day or tobacco equivalents or chew tobacco
Subjects who have undergone administration of any investigational device within 30 days of enrolment in the study
Conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance or unreliability
Physical or mental handicaps that would interfere with the ability to perform adequate oral hygiene
Pregnant women at screening

Secondary exclusion criteria at or after implant surgery:

Lack of primary stability of the implant (hand testing directly after surgery)
Inappropriate implant position for the prosthetic requirements (to be estimated before provisional restoration)
Major simultaneous augmentation procedures (at surgery)
X-ray of implant does not show the implant from first bone contact to apical tip (at surgery)

Arm && Interventions

Group	Intervention	Description
FullCeram implant	FullCeram implant	Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm

Primary Outcome Measures

Name	Time	Method
The Implant Survival	Measured at 12 months +/- 4 weeks after implant placement	A surviving implant is an integrated implant in the patient's jaw bone at the time of assessment.

Secondary Outcome Measures

Name	Time	Method
The Implant Success	Measured at Week 26, Month 12, Month 24 and Month 36	According to Buser et al 1992 an implant will be deemed a success if all of the following success criteria apply. * Absence of persisting subjective discomfort such as pain, foreign body perception and or dysaesthesia (painful sensation) * Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics) * Absence of implant mobility on manual palpation * Absence of any continuous peri-implant radiolucency
Mean Bone Level Changes (Distal and Mesial)	Measured at Week 26, Month 12, Month 24 and Month 36	A radiographic stent was produced to have a standard measurement. The distal and mesial bone levels were combined into a single value by averaging the two values. Negative bone level changes representing bone loss between baseline and follow-up visits, vice versa positive changes representing bone gain.
The Implant Survival	Measured at Week 26, Month 24 and Month 36	A surviving implant is an integrated implant in the patient's jaw bone at the time of assessment.

Locations (3): Medizinische Hochschule Hannover Klinik und Poliklinik fuer Mund-, Kiefer- und Gesichtschirurgie
🇩🇪
Hannover, Germany
Katharinenhospital
🇩🇪
Stuttgart, Germany
Oralchirurgie T1
🇩🇪
Munich, Germany